Triple negative breast cancer: A brief review of its characteristics and treatment options

Journal of Pharmacy Practice

Volumn 25, Issue 3, 2012, Pages 319-323

  Griffiths, Carrie L ^a   Olin, Jacqueline L ^b  

^a North Texas Veterans Health Care System   (United States)

^b WINGATE UNIVERSITY   (United States)

Author keywords

triple negative breast cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INIPARIB; IRINOTECAN; IXABEPILONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PROGESTERONE RECEPTOR; SUNITINIB; VELIPARIB;

ACNE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; RACE DIFFERENCE; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84866269413     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012442062     Document Type: Review

References (24)

1. American Cancer Society, Inc. Surveillance and Health Policy Research 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-026210.pdf. Accessed May 1, 2011.
2. Atlanta, GA: American Cancer Society ; 2010 :
3. http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/ breast-cancer-what-is-breast-cancer. Accessed May 25, 2011.
4. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010 ; 12 (5). R68
5. Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol. 2006 ; 24 (18S). 508
6. Gonzalez-Angulo AM, Chen H, Timms K, et al. Incidence and outcome of BRCA mutation carriers with triple receptor-negative breast cancer (TNBC). J Clin Oncol. 2010 ;:
7. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011 ; 16 ((Suppl 1 )). 1-11
8. Carey L, Perou C, Livasy C, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006 ; 295 (21). 2492-2502 (Pubitemid 43854964)
9. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008 ; 109 (1). 123-139 (Pubitemid 351538762)
10. National Comprehensive Cancer Network (NCCN). The NCCN Guidelines Version 2.2011. www.nccn.org. Accessed June 5, 2011.
11. Bauer KM, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007 ; 109 (9). 1721-1728 (Pubitemid 46668532)
12. Leidke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 ; 26 (8). 1275-1281
13. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer. 2008 ; 113 (10). 2638-2645
14. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 ; 363 (20). 1938-1948
15. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010 ; 16 (1). 53-61
16. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 ; 28 (7). 1145-1153
17. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009 ; 20 (8). 1319-1329
18. Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011 ; 22 (4). 848-856
19. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011 ; 364 ((3)). 205-214
20. Carey LA, Rugo HS, Marcom PK. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 2008 ; 26: 43s
21. O'Shaughnessy J, Osborne C, Pippen JE, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat. 2007 ; 106: s32
22. Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2 negative (triple-negative) breast cancer. Anticancer Drugs. 2007 ; 18 (7). 835-837 (Pubitemid 46975972)
23. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm237172. htm. Accessed June 5, 2011.
24. Carlson RH.. Bevacizumab: Public opinion might trump science. Lan Oncol. 2011 ; 12: 730